Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer

Cell

Volumn 165, Issue 5, 2016, Pages 1092-1105

  Wang, Weimin ^a   Kryczek, Ilona ^a   Dostál, Lubomír ^b   Lin, Heng ^a   Tan, Lijun ^a   Zhao, Lili ^a   Lu, Fujia ^a   Wei, Shuang ^a   Maj, Tomasz ^a   Peng, Dongjun ^a   He, Gong ^a   Vatan, Linda ^a   Szeliga, Wojciech ^a   Kuick, Rork ^a   Kotarski, Jan ^c   Tarkowski, Rafał ^c   Dou, Yali ^a   Rattan, Ramandeep ^d   Munkarah, Adnan ^d   Liu, J Rebecca ^a,e   Zou, Weiping ^a,b,e   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPORTER; CISPLATIN; CYSTEINE; CYSTINE; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; GLUTAMIC ACID; GLUTATHIONE; JANUS KINASE; STAT1 PROTEIN; ANTINEOPLASTIC AGENT;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL NUCLEUS; CONTROLLED STUDY; DRUG ACCUMULATION; EFFECTOR CELL; ENZYME INDUCTION; FEMALE; FIBROBLAST; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; METABOLIC REGULATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; STROMA CELL; TRANSCRIPTION TERMINATION; TUMOR IMMUNITY; ANIMAL; CELL CULTURE TECHNIQUE; DRUG RESISTANCE; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLASTS; GLUTATHIONE; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED NOD; MICE, NUDE; OVARIAN NEOPLASMS;

EID: 84964637801     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.04.009     Document Type: Article

References (32)

1. D.C. Binder, Y.X. Fu, and R.R. Weichselbaum Radiotherapy and immune checkpoint blockade: potential interactions and future directions Trends Mol. Med. 21 2015 463 465
2. H.H. Chen, and M.T. Kuo Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy Met. Based Drugs 2010 2010 430939
3. T.X. Cui, I. Kryczek, L. Zhao, E. Zhao, R. Kuick, M.H. Roh, L. Vatan, W. Szeliga, Y. Mao, D.G. Thomas, and et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2 Immunity 39 2013 611 621
4. T.J. Curiel, S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K.L. Knutson, B. Daniel, M.C. Zimmermann, and et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat. Med. 9 2003 562 567
5. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, M. Burow, and et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med. 10 2004 942 949
6. J.C. Dabrowiak, J. Goodisman, and A.K. Souid Kinetic study of the reaction of cisplatin with thiols Drug Metab. Dispos. 30 2002 1378 1384
7. S. Domcke, R. Sinha, D.A. Levine, C. Sander, and N. Schultz Evaluating cell lines as tumour models by comparison of genomic profiles Nat. Commun. 4 2013 2126
8. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M. Castedo, and G. Kroemer Molecular mechanisms of cisplatin resistance Oncogene 31 2012 1869 1883
9. T. Ishikawa, and F. Ali-Osman Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance J. Biol. Chem. 268 1993 20116 20125
10. T. Ishimoto, O. Nagano, T. Yae, M. Tamada, T. Motohara, H. Oshima, M. Oshima, T. Ikeda, R. Asaba, H. Yagi, and et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth Cancer Cell 19 2011 387 400
11. R. Kalluri, and M. Zeisberg Fibroblasts in cancer Nat. Rev. Cancer 6 2006 392 401
12. M. Kraman, P.J. Bambrough, J.N. Arnold, E.W. Roberts, L. Magiera, J.O. Jones, A. Gopinathan, D.A. Tuveson, and D.T. Fearon Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha Science 330 2010 827 830
13. R. Kröning, A.K. Lichtenstein, and G.T. Nagami Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines Cancer Chemother. Pharmacol. 45 2000 43 49
14. Y. Lee, S.L. Auh, Y. Wang, B. Burnette, Y. Wang, Y. Meng, M. Beckett, R. Sharma, R. Chin, T. Tu, and et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment Blood 114 2009 589 595
15. M. Loeffler, J.A. Krüger, A.G. Niethammer, and R.A. Reisfeld Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake J. Clin. Invest. 116 2006 1955 1962
16. V.I. Lushchak Glutathione homeostasis and functions: potential targets for medical interventions J. Amino Acids 2012 2012 736837
17. J. Mårtensson, and A. Meister Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester Proc. Natl. Acad. Sci. USA 86 1989 471 475
18. B.C. Özdemir, T. Pentcheva-Hoang, J.L. Carstens, X. Zheng, C.C. Wu, T.R. Simpson, H. Laklai, H. Sugimoto, C. Kahlert, S.V. Novitskiy, and et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival Cancer Cell 25 2014 719 734
19. D. Peng, I. Kryczek, N. Nagarsheth, L. Zhao, S. Wei, W. Wang, Y. Sun, E. Zhao, L. Vatan, W. Szeliga, and et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy Nature 527 2015 249 253
20. I. Revet, L. Feeney, S. Bruguera, W. Wilson, T.K. Dong, D.H. Oh, D. Dankort, and J.E. Cleaver Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents Proc. Natl. Acad. Sci. USA 108 2011 8663 8667
21. E. Sato, S.H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A.A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, and et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc. Natl. Acad. Sci. USA 102 2005 18538 18543
22. T. Soussi, D. Hamroun, L. Hjortsberg, J.M. Rubio-Nevado, J.L. Fournier, and C. Béroud MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer Hum. Mutat. 31 2010 1020 1025
23. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, J. Du, A. Davis, M.M. Mongare, J. Gould, D.T. Frederick, and et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
24. S.L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
25. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 2005 307 320
26. T.L. Yeung, C.S. Leung, K.K. Wong, G. Samimi, M.S. Thompson, J. Liu, T.M. Zaid, S. Ghosh, M.J. Birrer, and S.C. Mok TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment Cancer Res. 73 2013 5016 5028
27. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M.N. Liebman, and et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N. Engl. J. Med. 348 2003 203 213
28. W. Zhang, D. Trachootham, J. Liu, G. Chen, H. Pelicano, C. Garcia-Prieto, W. Lu, J.A. Burger, C.M. Croce, W. Plunkett, and et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia Nat. Cell Biol. 14 2012 276 286
29. E. Zhao, T. Maj, I. Kryczek, W. Li, K. Wu, L. Zhao, S. Wei, J. Crespo, S. Wan, L. Vatan, and et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction Nat. Immunol. 17 2016 95 103
30. L. Zitvogel, O. Kepp, and G. Kroemer Decoding cell death signals in inflammation and immunity Cell 140 2010 798 804
31. W. Zou Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat. Rev. Cancer 5 2005 263 274
32. W. Zou, J.D. Wolchok, and L. Chen PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Sci. Transl. Med. 8 2016 328rv4